Mechanisms of tumour escape from immune surveillance

1. Azuma M.: Role of the glucocorticoid-induced TNFR-related protein (GITR)-GITR ligand pathway in innate and adaptive immunity. Crit Rev Immunol 2010, 30, 547-557.10.1615/CritRevImmunol.v30.i6.4021175417Search in Google Scholar

2. Baltz K.M., Krusch M., Bringmann A., Brossart P., Mayer F., Kloss M., Baessler T., Kumbier I., Peterfi A., Kupka S., Kroeber S., Menzel D, Radsak M.P., Rammensee H.G., Salih H.R.: Cancer immunoediting by GITR (glucocorticoid-induced TNFrelated protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007, 21, 2442-2454.10.1096/fj.06-7724com17360848Search in Google Scholar

3. Beatty G.L., Gladney W.L.: Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015, 21, doi: 10.1158/1078-0432.Search in Google Scholar

4. Beyer M., Schultze J.L.: Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009, 15, 1879-1892.10.2174/13816120978845321119519430Search in Google Scholar

5. Biller B.J., Elmslie R.E., Burnett R.C., Avery A.C., Dow S.W.: Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 2007, 116, 69-78.10.1016/j.vetimm.2006.12.00217224188Search in Google Scholar

6. Biswas S.K., Lewis C.E.: NF-κB as a central regulator of macrophage function in tumors. J Leukoc Biol 2010, 88, 877-884.10.1189/jlb.031015320573802Search in Google Scholar

7. Candolfi M., Curtin J.F., Yagiz K., Assi H., Wibowo M.K., Alzadeh G.E., Foulad D., Muhammad A.K.M.G., Salehi S., Keech N., Puntel M., Liu Ch., Sanderson N.R., Kroeger K.M., Dunn R., Martins G., Lowenstein P.R., Castro M.G.: B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 2011, 13, 947-960.10.1593/neo.11024320157122028620Search in Google Scholar

8. Cohen A.D., Schaer D.A., Liu C., Li Y., Hirschhorn- Cymmerman D., Kim S.C.: Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 2010, 5, e10436. doi:10.1371/journal.pone.0010436.Search in Google Scholar

9. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A.: Cancer related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30, 1073-1081.10.1093/carcin/bgp12719468060Search in Google Scholar

10. Condamine T., Ramachandran I., Youn J., Gabrilovich D.I.: Regulation of tumor metastasis by myeloid-derived suppressor cells. Ann Rev Med 2015, 66, 97-110.10.1146/annurev-med-051013-052304432472725341012Search in Google Scholar

11. Contardi E., Palmisano G.L., Tazzari P.L., Martelli A.M., Falà F., Fabbi M., Kato T., Lucarelli E., Donati D., Polito L., Bolognesi A., Ricci F., Salvi S., Gargaglione V., Mantero S., Alberghini M., Ferrara G.B., Pistillo M.P.: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005, 117, 538-550.10.1002/ijc.2115515912538Search in Google Scholar

12. Facciabene A., Motz G.T., Coukos G.: T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012, 72, 2162-2171.10.1158/0008-5472.CAN-11-3687334284222549946Search in Google Scholar

13. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pagès F.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.10.1126/science.112913917008531Search in Google Scholar

14. Garden O.A., Pinheiro D., Cunninghamb F.: All creatures great and small: regulatory T cells in mice, humans, dogs and other domestic animal species. Int Immunopharmacol 2011, 11, 576-588.10.1016/j.intimp.2010.11.00321093606Search in Google Scholar

15. Gastman B.R., Johnson D.E., Whiteside T.L., Rabinowich H.: Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 2000, 95, 2015-2023.10.1182/blood.V95.6.2015Search in Google Scholar

16. Goldberg M.V., Drake C.G.: LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011, 344, 269-278.10.1007/82_2010_114469601921086108Search in Google Scholar

17. Hayashi T., Horiuchi A., Sano K., Hiraoka N., Kasai M., Ichimura T., Sudo T., Tagawa Y., Nishimura R., Ishiko O., Kanai Y., Yaegashi N., Aburatani H., Shiozawa T., Konishi I.: Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Sci Rep 2011, 1, 180, doi: 10.1038/srep00180.Search in Google Scholar

18. Huye L.E., Dotti G.: Designing T cells for cancer immunotherapy. Discov Med 2010, 47, 297-303.Search in Google Scholar

19. Ichim T.E., Zhong Z., Kaushal S., Zheng X., Ren X., Hao X., Joyce J.A., Hanley H.H., Riordan N.H., Koropatnick J., Bogin V., Minev B.R., Min W., Tullis R.H.: Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med 2008, 6, 37 http://www.translationalmedicine.com/content/6/1/37.10.1186/1479-5876-6-37250447418644158Search in Google Scholar

20. Jagła M., Cichocka-Jarosz E.: Regulatory lymphocytes. Alerg Astma Immun 2007, 12, 22-29.Search in Google Scholar

21. Ji H.B., Liao G., Faubion W.A., Abadia-Molina A.C., Cozzo C., Laroux F.S., Caton A., Terhorst C.: Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol 2004, 172, 5823-5827.10.4049/jimmunol.172.10.582315128759Search in Google Scholar

22. Jiabei H., Ying H., Mingming H., Baolan L.: Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 2015, 5, doi:10.1038/srep13110.Search in Google Scholar

23. Johnsen A.K., Templeton D.J., Sy M., Harding C.V.: Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999, 163, 4224-4231.10.4049/jimmunol.163.8.4224Search in Google Scholar

24. Kaufman H.L., Disis M.L.: Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 2004, 113, 664-667.10.1172/JCI2114835132714991063Search in Google Scholar

25. Kim P., Armstrong T., Song H., Wolpoe M., Weiss V., Manning E., Huang L., Murata S., Sgouros G., Emens L., Reilly R., Jaffe E.: Antibody association with HER-2/neu-targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 2008, 188, 1700-1711.10.1172/JCI34333228979718398507Search in Google Scholar

26. Kim R., Emi M., Tanabe K.: Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 2006, 119, 254-264.10.1111/j.1365-2567.2006.02430.x178235517005005Search in Google Scholar

27. Kumar V., Patel S., Tcyganov E., Gabrilovich D.I.: The nature of myeloid derived suppressor cells in the tumor microenvironment. Trends Immunol 2016, 37, 208-220.10.1016/j.it.2016.01.004477539826858199Search in Google Scholar

28. Lewkowicz P., Lewkowicz N., Tchórzewski H.: CD4+CD25+ T regulatory cells in pathophysiology and therapy of immunological disorders. Postępy Hig Med Dośw 2005, 59, 371-376.Search in Google Scholar

29. Lopez J., Tait S.W.G.: Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer 2015, 112, 957-962.10.1038/bjc.2015.85436690625742467Search in Google Scholar

30. Luczyński W., Krawczuk-Rybak M., Stasiak-Barmuta A.: Myeloid-derived suppressor cells - the new mechanism of immunosuppression in cancer. Postępy Hig Med Dośw 2008, 21, 18-22.Search in Google Scholar

31. Luke J.L., Ott P.A.: PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget 2015, 6, 3479-3492.10.18632/oncotarget.2980441413025682878Search in Google Scholar

32. Maeda H., Shiraishi A.: TGF-beta contributes to the shift toward Th-2 type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996, 156, 73-78.10.4049/jimmunol.156.1.73Search in Google Scholar

33. Mougiakakos D.: Regulatory T cells in colorectal cancer: from biology to prognostic relevance. Cancers 2011, 3, 1708-1731.10.3390/cancers3021708375738624212779Search in Google Scholar

34. Nishikawa H., Sakaguchi S.: Regulatory T cells in tumor immunity. Int J Cancer 2010, 127, 759-767.10.1002/ijc.2542920518016Search in Google Scholar

35. Oleinika K., Nibbs R.J., Graham G.J., Fraser A.R.: Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 2013, 171, 36-45.10.1111/j.1365-2249.2012.04657.x353009323199321Search in Google Scholar

36. Pinheiro D., Singh Y., Grant Ch.R., Appleton R.C., Sacchini F., Walker K.L.R., Chadbourne A.H., Palmer Ch.A., Armitage- Chan E., Thompson I., Williamson L., Cunningham F., Garden O.A.: Phenotypic and functional characterization of a CD4+CD25high FOXP3high regulatory T-cell population in the dog. Immunology 2010, 132, 111-122.10.1111/j.1365-2567.2010.03346.x301508120880379Search in Google Scholar

37. Poggi A., Massaro A.M., Negrini S., Contini P., Zocchi M.R.: Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol 2005, 174, 2653-2660.10.4049/jimmunol.174.5.265315728472Search in Google Scholar

38. Poggi A., Zocchi M.R.: Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp 2006, 54, 323-333.10.1007/s00005-006-0038-717031467Search in Google Scholar

39. Ryba M., Myśliwska J.: CD4+CD25+Foxp3+ T lymphocytes: naturally occurring T regulatory lymphocytes. Pediatr Endocrinol Diabetes Metab 2010, 16, 289-294.Search in Google Scholar

40. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.T., Ohtani H., Old L.J., Odunsi K.: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102, 18538-18543.10.1073/pnas.0509182102131174116344461Search in Google Scholar

41. Sayers T.J.: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011, 60, 1173-1180.10.1007/s00262-011-1008-421626033Search in Google Scholar

42. Schreiber H., Wu T.H., Nachman J., Kast W.M.: Immunodominance and tumor escape. Semin Cancer Biol 2002, 12, 25-31.10.1006/scbi.2001.040111926408Search in Google Scholar

43. Schreiber R.D., Old L.J., Smyth M.J.: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565-1570.10.1126/science.120348621436444Search in Google Scholar

44. Shevach E.M., Stephens G.L.: The GITR-GITRL interaction: costimulation or contrasuppression of regulatory activity? Nature Rev Immunol 2006, 6, 613-618.10.1038/nri186716868552Search in Google Scholar

45. Sica A., Schioppa T., Mantovani A., Allavena P.: Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006, 42, 717-727.10.1016/j.ejca.2006.01.00316520032Search in Google Scholar

46. Staveley-O’Carroll K., Sotomayor E., Montgomery J., Borello I., Hwang L., Fein S., Pardoll D., Levitsky H.: Induction of antigenspecific T cell anergy: an early event in the course of tumour progression. Proc Natl Acad Sci USA 1998, 95, 1179-1183.10.1073/pnas.95.3.1178187129448305Search in Google Scholar

47. Tiemessen M.M., Jagger A.L., Evans H.G., van Herwijnen M.J., John S., Taams L.S.:CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007, 104, 19446-19451.10.1073/pnas.0706832104214830918042719Search in Google Scholar

48. Upadhyay R., Hammerich L., Peng P., Brown B., Merad M., Brody J.D.: Lymphoma: immune evasion strategies. Cancers 2015, 7, 736-762.10.3390/cancers7020736449168225941795Search in Google Scholar

49. Wesołowski R., Markovitz J., Carson W.E.: Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013, 1, 10 http://www.immunotherapyofcancer.org/content/1/1/10.10.1186/2051-1426-1-10401989524829747Search in Google Scholar

50. Wolchok J.D., Chan T.A.: Cancer: Antitumour immunity gets a boost. Nature 2014, 515, 496-498.10.1038/515496a659227625428495Search in Google Scholar

51. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.L., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., Tangsombatvisit S., Grosso J.F., Netto G., Smeltzer M.P., Chaux A., Utz P.J., Workman C.J., Pardoll D. M., Korman A.J., Drake C. G., Vignali D.A.A.: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72, 917.10.1158/0008-5472.CAN-11-1620328815422186141Search in Google Scholar

52. Xiao-Feng Qin F.: Dynamic behavior and function of Foxp3 regulatory T cells in tumor bearing host. Cell Mol Immunol 2009, 6, 3-13.10.1038/cmi.2009.2400254519254475Search in Google Scholar

53. Yang Y.: Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 2015, 125, 3335-3337.10.1172/JCI83871458831226325031Search in Google Scholar

54. Yang Z.Z., Ansell S.M.: The role of Treg cells in the cancer immunological response. Am J Immunol 2009, 5, 17-28.10.3844/ajisp.2009.17.28Search in Google Scholar

55. Yuan A., Hsiao Y.J., Chen H.J., Chen H.W., Ho Ch. Ch., Chen Y.Y., Liu Y.Ch., Hong T.H., Yu S.L., Chen J.J.W., Yang P.Ch.: Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep 2015, 5, 1-12. 10.1038/srep14273458584326399191Search in Google Scholar